Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 Study of Omadacycline vs Moxifloxacin for Community-Acquired Bacterial Pneumonia
2013-004071-13Phase 3Completed
- Sponsor
- Paratek Pharmaceuticals
- Start
- Apr 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of omadacycline in community acquired pneumonia (CAP) and community-acquired pneumonia (CAP) (2 arms), sponsored by Paratek Pharmaceuticals. Started Apr 2015; status: completed.
02
Drugs
omadacycline
03
Conditions
community acquired pneumonia (CAP)community-acquired pneumonia (CAP)
Beyond the preview
Go deeper on 2013-004071-13.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-004071-13.